Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome

被引:0
作者
E. ©akal
M. Ozkaya
Y. Engin-Ustun
Y. Ustun
机构
[1] Yuksek Ihtisas Education and Research Hospital,Department of Endocrinology
[2] Sutcu Imam University Medical Faculty,Department of Endocrinology
[3] Inonu University Medical Faculty,Department of Obstetrics & Gynecology
来源
Journal of Endocrinological Investigation | 2011年 / 34卷
关键词
Polycystic ovary syndrome; lipocalin-2; insulin resistance;
D O I
暂无
中图分类号
学科分类号
摘要
Background: Our aim was to investigate levels of lipocalin-2 and its relationship with metabolic factors in women with polycystic ovary syndrome (PCOS). Materials/Subjects and methods: In this cross-sectional study, two groups of women were studied: group 1 consisted of women with PCOS (no.=30), and group 2 consisted of control women with normal ovulatory function (no.=30). The circulating levels of free testosterone (T), DHEAS, glucose, insulin, triglycerides (TG), HDL, LDL and lipocalin were measured. Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR). In order to determine a lipocalin value indicating insulin resistance, receiver operating characteristic (ROC) curves were established. Results: Serum lipocalin was significantly higher in PCOS subjects (54.26±15.58 vs 26.09±7.47 ng/ml, p=0.0001). We found a close correlation between lipocalin and insulin, lipocalin and HOMA-IR, lipocalin and T, and lipocalin and DHEAS. A cut-off level of >39.54 ng/ml for serum lipocalin has a predictive value for insulin resistance of 81% sensitivity and 82.1% specificity. Conclusion: In our study, lipocalin-2 levels were found to be significantly higher in women with PCOS compared to body mass index-matched controls. Serum lipocalin-2 may prove to be a useful marker for insulin resistance in patients with PCOS.
引用
收藏
页码:97 / 100
页数:3
相关论文
共 98 条
[1]  
Homburg R(2002)What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome Hum Reprod 17 2495-9
[2]  
Ehrmann DA(1997)Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 524-30
[3]  
Cavaghan MK(2000)Polycystic ovary syndrome: a risk factor for cardiovascular disease Br J Obstet Gynecol 107 11-8
[4]  
Imperial J(2000)Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse Biochim Biophys Acta 1482 272-83
[5]  
Sturis J(2007)Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarkerfor renal tubulointerstitial injury in IgA nephropathy Clin Immunol 123 227-34
[6]  
Rosenfield RL(2008)Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 158 525-31
[7]  
Polonsky KS(2004)Clinical assessment of body hair growth in women Fertil Steril 81 19-25
[8]  
Rajkhowa M(1962)Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man J Clin Endocrinol Metab 21 1440-7
[9]  
Glass MR(1985)Use of receiver operating characteristic curves to evaluate the clinical performance of analytical systems Diabetologia 28 412-9
[10]  
Rutherford AJ(1981)Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome Clin Chem 27 1569-74